medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 6

<< Back Next >>

Med Int Mex 2021; 37 (6)

Thrombotic alterations in cancer: a practical review

Arrieta-Sibaja JD, Roldán-Tabares MD, Martínez-Sanchez LM

Language: Spanish
References: 68
Page: 998-1007
PDF size: 215.37 Kb.


ABSTRACT

The association between cancer and vascular thrombosis has been known since 1865, when Trousseau reported the association between migratory thrombophlebitis in patients with malignant neoplasms; it is now known that cancer patients have a higher risk than the general population for developing vascular thrombosis for the interactions between the patient’s factors, the tumor, the factors related to the treatment and certain biomarkers of the disease; however, the clinical presentation of patients with vascular thrombosis does not show differences between the group of patients with cancer, compared with those who do not. Recent studies show that the use of monoclonal antibodies as cancer stromal targeting therapy selectively extravasates tumors by their angiogenesis. There is a relationship between neoplasms and thrombosis to the point that one can predispose directly to the concurrence of the other. Early diagnosis of thrombosis is important as it is the second cause of death in oncological patients and treatment should focus on procedures to treat thrombosis and also to treat neoplasia.


REFERENCES

  1. Sack GH Jr, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977; 56 (1): 1-37. https://doi.org/10.1097/00005792-197756010- 00001.

  2. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015; 13 (6): 1028-35. doi: 10.1111/jth.12923.

  3. Amer MH. Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res 2013; 5: 165-78. doi: 10.2147/CMAR.S47094.

  4. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 9 (7): e1001275. doi: 10.1371/journal.pmed.1001275.

  5. Ravikumar R, Lim CS, Davies AH. The role of new oral anticoagulants (NOACs) in cancer patients. Adv Exp Med Biol 2017; 906: 137-148. doi: 10.1007/5584_2016_112.

  6. Tikhomirova I, Petrochenko E, Malysheva Y, Ryabov M, Kislov N. Interrelation of blood coagulation and hemorheology in cancer. Clin Hemorheol Microcirc 2016; 64 (4): 635-644. doi: 10.3233/CH-168037.

  7. Paneesha S, McManus A, Arya R, Scriven N, Farren T, Nokes T, et al. Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost 2010; 103 (2): 338-43. doi: 10.1160/TH09-06-0397.

  8. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017; 130 (13): 1499-1506. doi: 10.1182/blood-2017-03-743211.

  9. Hisada Y, Geddings JE, Ay C, Mackman N. Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost 2015; 13 (8): 1372-82. doi: 10.1111/jth.13009.

  10. Vedovati MC, Giustozzi M, Bonitta G, Agnelli G, Becattini C. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network metaanalysis. Thromb Res 2018; 170: 175-180. doi: 10.1016/j. thromres.2018.08.023.

  11. Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 2008; 149 (5): 323-33. doi: 10.7326/0003-4819-149-5- 200809020-00007.

  12. Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res 2018; 164 Suppl 1: S112-S118. doi: 10.1016/j. thromres.2018.01.028.

  13. Soff GA. Pathophysiology and management of thrombosis in cancer: 150 years of progress. J Thromb Thrombolysis 2013; 35 (3): 346-51. doi: 10.1007/s11239-013-0897-9.

  14. Boccaccio C, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol 2009; 27 (29): 4827-33. doi: 10.1200/JCO.2009.22.7199.

  15. Ligi D, Croce L, Mannello F. Chronic venous disorders: the dangerous, the good, and the diverse. Int J Mol Sci 2018; 19 (9): 2544. doi: 10.3390/ijms19092544.

  16. Shabani-Varaki E, Gargiulo GD, Penkala S, Breen PP. Peripheral vascular disease assessment in the lower limb: A review of current and emerging non-invasive diagnostic methods. Biomed Eng Online 2018; 17 (1): 61. doi: 10.1186/s12938-018-0494-4.

  17. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood 2015; 126 (5): 582-8. doi: 10.1182/blood-2014-08-531582.

  18. Raffetto JD, Mannello F. Pathophysiology of chronic venous disease. Int Angiol 2014; 33 (3): 212-221.

  19. Fuchigami H, Manabe S, Yasunaga M, Matsumura Y. Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. Sci Rep 2018; 8 (1): 14211. doi: 10.1038/s41598-018-32601-0.

  20. Falanga A, Santoro A, Labianca R, De Braud F, Gasparini G, D’Alessio A, et al. Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. J Thromb Res 2016; 140 Suppl 1: S55-9. doi: 10.1016/S0049-3848(16)30099-8.

  21. Di Nisio, M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet 2016; 388 (10063): 3060- 3073. doi: 10.1016/S0140-6736(16)30514-1.

  22. Noble S. The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgrad Med J 2007; 83 (985): 671-4. doi: 10.1136/ pgmj.2007.061622.

  23. Martínez del Prado, Casados DI. Epidemiología, etiopatogenia, factores de riesgo y pronóstico de la ETV. Diagnóstico de la ETV: TEP, TVP y trombosis asociada a catéter. En: II Consenso SEOM sobre la enfermedad tromboembólica en pacientes con cáncer. Barcelona: Esmon Publicidad; 2013: 9-30.

  24. Martínez MT, Villaronga OP, Rodríguez CC, López MJ, Aguirre A, Echarte-Pazo JL. Presentación clínica del tromboembolismo pulmonar en urgencias: comparación con estudios previos. Emergencias 2010; 22 (2): 113-116.

  25. Le Gal G, Righini M, Roy PM, Sánchez O, Aujesky D, Bounameaux H, Perrier A. Prediction of pulmonary embolism in the emergency department: The revised Geneva Score. Ann Intern Med 2006; 144: 165-71. doi: 10.7326/0003- 4819-144-3-200602070-00004.

  26. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98 (4): 756-64.

  27. Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol 2014; 8: 129-37. doi: 10.4137/CMO.S18991.

  28. Kyriazi V, Theodoulou E. Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch Pathol Lab Med 2013; 137 (9): 1286-95. doi: 10.5858/ arpa.2012-0490-RA.

  29. Agnelli G, Verso M, Mandalà M, Gallus S, Cimminiello C, Apolone G, et al. A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med 2014; 9 (5): 559-67. doi: 10.1007/ s11739-013-0985-z.

  30. Schiffer C, Mangu P, Wade JC, Camp-Sorrell D, Cope D, El- Rayes B, et al. Central venous catheter care for the patient with cancer: American Society of Clinical oncology clinical practice guideline. J Clin Oncol 2013; 31: 1357-70. doi: 10.1200/JCO.2012.45.5733.

  31. Young AM, Billingham LJ, Begum G, Kerr D, Hughes AI, Rea D, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WarP): an open-label randomised trial. Lancet 2009; 373: 567-74. doi: 10.1016/ S0140-6736(09)60205-1.

  32. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002; 32: 84-8.

  33. Geerts W. Central venous catheter-related thrombosis. Hematology Am Soc Hematol Educ Program 2014; 2014: 306-11. doi: 10.1182/asheducation-2014.1.306.

  34. Kirwan CC, McCollum CN, McDowell G, Byrne GJ. Investigation of proposed mechanisms of chemotherapy induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis. Clin Appl Thromb Hemost 2015; 21 (5): 420-7. doi: 10.1177/1076029615575071.

  35. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119 (3): 648-55. doi: 10.1002/cncr.27772.

  36. Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist 2013; 18 (12): 1321-9. doi: 10.1634/theoncologist.2013-0226.

  37. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104 (12): 2822-9. doi: 10.1002/cncr.21496.

  38. Lloyd AJ, Dewilde S, Noble S, Reimer E, Lee AYY. What impact does venous thromboembolism and bleeding have on cancer patients’ quality of life? Value Health 2018; 21 (4): 449-455. doi: 10.1016/j.jval.2017.09.015.

  39. Kuderer N, Ortel T, Francis C. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009: 27; 4902-4911. doi: 10.1200/ JCO.2009.22.4584.

  40. Verso M, Franco L, Giustozzi M, Becattini C, Agnelli G. Treatment of venous thromboembolism in patients with cancer: What news from clinical trials? Thromb Res 2018; 164 (1): S168-S171. doi: 10.1016/j.thromres.2018.01.031.

  41. Kourelis TV, Wysokinska EM, Wang Y, Yang P, Mansfield AS, Tafur AJ. Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. Lung Cancer 2014 ;86 (3): 358-62. doi: 10.1016/j. lungcan.2014.10.003.

  42. Panova-Noeva M, Neu MA, Eckerle S, Spix C, Schneider A, Schmidtmann I, et al. Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer. Clin Res Cardiol 2019 Apr; 108 (4): 438-447. doi: 10.1007/s00392-018-1374-4.

  43. Jodra S, Andrés A, Abad L. Trombosis venosa inusual como primera manifestación de neoplasia pulmonar. Arch Bronconeumol 2015; 51 (3): e13-e18. DOI: 10.1016/j. arbres.2014.03.017.

  44. Abitia JC, Agredano S, Mariscal I, Ronquillo C, Villa G, Nava AH. Prothrombotic state in cancer patients. Residente: 2015; 10 (3): 166-172.

  45. Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RD, Heckbert S. Fibrin fragment D-Dimer and the risk of future venous thrombosis. Blood 2010; 101: 1243-8. doi: 10.1182/blood-2002-05-1416.

  46. Jianlong M, Diansheng Z, Jing R. Estimation of venous thromboembolism risk with thrombotic biomarkers in cancer patients. Zhonghua Zhong Liu Za Zhi 2015; 37 (4): 283-9.

  47. Diao D, Wang Z, Cheng Y, Zhang H, Guo Q, Song Y, et al. D-dimer: not just an indicator of venous thrombosis but a predictor of asymptomatic hematogenous metastasis in gastric cancer patients. PLoS One 2014; 9 (7): e101125. doi: 10.1371/journal.pone.0101125.

  48. Reitter EM, Kaider A, Ay C, Quehenberger P, Marosi C, Zielinski C, Pabinger I. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. J Thromb Haemost 2016; 14 (2): 294-305. doi: 10.1111/jth.13218.

  49. Mezouar S, Frère C, Darbousset R, Mege D, Crescence L, Dignat G. Role of platelets in cancer and cancerassociated thrombosis: Experimental and clinical evidences. Thromb Res 2016; 139; 65-76. doi: 10.1016/j. thromres.2016.01.006.

  50. Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized- controlled phase II trial (the Microtec study). Br J Haematol 2013; 160 (4): 530-7. doi: 10.1111/bjh.12163.

  51. Jacobs B, Obi A, Wakefield T. Diagnostic biomarkers in venous thromboembolic disease. J Vasc Surg Venous Lymphat Disord 2016; 4 (4): 508-17. doi: 10.1016/j.jvsv.2016.02.005.

  52. Pérez LD. Diagnóstico clínico de la trombosis venosa profunda. Rev Cubana Angiol Cir Vasc 2013; 14 (1suppl).

  53. Páramo JA. Diagnóstico y tratamiento de la trombosis venosa profunda. Rev Med Univ Navarra 2007; 51 (1): 13-7.

  54. Kahn S. The clinical diagnosis of deep venous thrombosis integrating incidence, risk factors, and symptoms and signs. Arch Intern Med 1998; 158: 2315-23. doi: 10.1001/ archinte.158.21.2315.

  55. Yazdani M, Lau CT, Lempel JK, Yadav R, El-Sherief AH, Azok JT, Renapurkar R. Historical evolution of imaging techniques for the evaluation of pulmonary embolism. Radiographics 2015; 35 (4): 1245-62. doi: 10.1148/rg.2015140280.

  56. Tilve-Gómez A, Rodríguez-Fernández P, Trillo-Fandiño L, Plasencia-Martínez JM. Imaging techniques used in the diagnostic workup of acute venous thromboembolic disease. Radiologia. 2017;59(4):329-342. doi: 10.1016/j. rx.2016.10.003.

  57. Pomero F, Dentali F, Borretta V, Bonzini M, Melchio R, Douketis JD, Fenoglio L. Accuracy of emergency physicianperformed ultrasonography in the diagnosis of deep-vein thrombosis: a systematic review and meta-analysis. Thromb Haemost 2013; 109 (1): 137-45. doi: 10.1160/TH12-07-0473.

  58. Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 2014; 134 (4): 774-82. doi: 10.1016/j.thromres.2014.06.020.

  59. Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 2018; 39 (47): 4208-4218. doi: 10.1093/eurheartj/ehx003.

  60. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical oncology clinical practice guideline update 2014. J Clin Oncol 2015; 33 (6): 654-6. doi: 10.1200/JCO.2014.59.7351.

  61. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e419S-e496S. doi: 10.1378/chest.11-2301.

  62. Cabral KP. Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis 2013; 36 (2):133- 40. doi: 10.1007/s11239-013-0929-5.

  63. Seaman S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence 2014; 8: 453-61. doi: 10.2147/PPA.S58595.

  64. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double dummy trial. Lancet Haematol 2016; 3 (8): e379-87. doi: 10.1016/S2352-3026(16)30057-6.

  65. Raskob GE, Büller HR, Segers A. Edoxaban for Cancer- Associated Venous Thromboembolism. N Engl J Med 2018; 379 (1): 95-96. doi: 10.1056/NEJMc1806646.

  66. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984; 53 (10): 2046-52. doi: 10.1002/1097-0142(19840515)53:10<2046::aidcncr2820531007> 3.0.co;2-f.

  67. Prandoni P. The treatment of venous thromboembolism in patients with cancer. Adv Exp Med Biol 2017; 906: 123-135. doi: 10.1007/5584_2016_111.

  68. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Expert Rev Anticancer Ther 2002; 2 (2): 227- 33. doi: 10.1586/14737140.2.2.227.




2020     |     www.medigraphic.com